Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

Presentation TCT 2016

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Presenter: Aaron V. Kaplan, Rachel Neubrander, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Debate: Is Left Atrial Appendage Closure Underutilized? No, NOACs Have the Best Efficacy and Safety Profile for Most Patients!

Presenter: Andreas Baumbach, David Hildick-Smith, Jai-Wun Park

November 01, 2016

Presentation TCT 2016

TCT 53: Thromboembolic Event Rate Is Elevated With Lower Adherence to Warfarin and NOACs

Presenter: Neal S. Kleiman, David F. Kong, Jeffrey R Winterfield

October 31, 2016

Presentation TCT 2016

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Presenter: Vivek Y. Reddy, Steven J. Yakubov

October 30, 2016

Presentation TCT 2016

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michelle O'Donoghue

October 30, 2016

Presentation Scripps 2016

Putting It All Together: Warfarin, NOAC or LAA Closure?

Presenter: Brian K. Whisenant

February 04, 2016

Presentation

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

Presenter: Vivek Y. Reddy

December 13, 2015

Presentation TCT 2015

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding Focused Commentary

Presenter: Martin B. Leon, Mark Reisman, Chet Rihal, Martin W Bergmann

October 15, 2015

Presentation TCT 2015

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding

Presenter: Martin B. Leon, Mark Reisman, Chet Rihal, Brij Maini

October 15, 2015

Presentation TCT 2015

Data Gaps and Future Trial Pathways: Possible Study Designs for New Devices, Anticoagulation Ineligible Patients, and Comparative NOAC Data

Presenter: Nicole Ibrahim, Saibal Kar, Zoltan G. Turi

October 14, 2015

Presentation TCT 2015

Which NOAC for Which Patient?

Presenter: David R. Holmes Jr., Vivek Y. Reddy, Christopher B. Granger

October 11, 2015

Presentation VEINS 2014

How to Interpret Hypercoagulable Laboratory Results while your patient is on one of the NOACs

Presenter: John R. Bartholomew

October 10, 2014

Presentation VEINS 2014

Prophylaxis and Medical Management of Venous Disease: Monitoring and Reversing NOACs

Presenter: James B. Froehlich

October 10, 2014

Presentation TCT 2014

Comparative Analysis of Warfarin and the NOACs: Differentiating Properties, Risks, and Benefits

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Jonathan L. Halperin

September 15, 2014

Presentation TCT 2014

Bleeding and Stroke Risk Assessment in Atrial Fibrillation: Choosing between Warfarin, NOACS, Antiplatelets, or Nothing?

Presenter: Matthew J. Price, Michael D. Ezekowitz

September 15, 2014

Advertisement

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Debate: Is Left Atrial Appendage Closure Underutilized? No, NOACs Have the Best Efficacy and Safety Profile for Most Patients!

TCT 53: Thromboembolic Event Rate Is Elevated With Lower Adherence to Warfarin and NOACs

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Putting It All Together: Warfarin, NOAC or LAA Closure?

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding Focused Commentary

LAA Closure vs Pharmacotherapy (Including NOACs) in a Patient With AF and Intermediate Risk of Bleeding

Data Gaps and Future Trial Pathways: Possible Study Designs for New Devices, Anticoagulation Ineligible Patients, and Comparative NOAC Data

Which NOAC for Which Patient?

How to Interpret Hypercoagulable Laboratory Results while your patient is on one of the NOACs

Prophylaxis and Medical Management of Venous Disease: Monitoring and Reversing NOACs

Comparative Analysis of Warfarin and the NOACs: Differentiating Properties, Risks, and Benefits

Bleeding and Stroke Risk Assessment in Atrial Fibrillation: Choosing between Warfarin, NOACS, Antiplatelets, or Nothing?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content